GlassScriptPhysician profile
Gena M Ettinger
NPI 1578815304
$8,534.44
in general payments reported to CMS, 2019-2025
13 companies · $6,869 in 2025
The $6,869 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.14 · 2023: $27.11 · 2024: $1,624 · 2025: $6,869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,645 · Food and Beverage: $3,556 · Travel and Lodging: $1,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,645.00 |
| Food and Beverage | $3,555.92 |
| Travel and Lodging | $1,319.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $5,766.86 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $1,092.61 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $506.07 | 2024 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $325.24 | 2022-2025 | Xifaxan |
| Lilly USA, LLC | $324.69 | 2024-2025 | Omvoh |
| Pfizer INC. | $142.64 | 2024 | |
| Ironwood Pharmaceuticals, INC | $134.12 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.49 | 2024-2025 | Entyvio |
| Mirum Pharmaceuticals, INC. | $59.58 | 2025 | Livmarli |
| Celltrion USA INC. | $32.05 | 2024 | Vegzelma |
| Janssen Biotech, INC. | $29.61 | 2025 | Tremfya |
| Acclarent, INC | $27.11 | 2023 | Relieva Spinplus |
| Genzyme Corporation | $24.37 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gena Ettinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.